Replies to post #239340 on Biotech Values

[DewDiligence]

CHMP approves PFE’s Abrocitinib for_moderate/severe atopic dermatitis:

https://finance.yahoo.com/news/pfizer-abrocitinib-receives-positive-chmp-115000136.html

Abrocitinib is already approved for atopic dermatitis in Japan, and now it will be approved in the EU following rubber-stamping by the EU Commission in a couple of months. It figures to be a needle-moving drug even for a company as large as PFE. Abrocitinib is a pill that has better efficacy than market-leading (injectable) Dupixent from SNY/REGN (#msg-165687423).

[DewDiligence]

SNY/REGN—FDA approves Dupixent for eosinophilic esophagitis:

https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-eosinophilic-esophagitis-chronic-immune-disorder

This the first FDA-approved drug for the indication.